First Week of OCUL September 18th Options Trading

The article outlines option strategies on Ocular Therapeutix (OCUL): a $11.00 put trading with a $2.95 bid would set an effective share cost basis of $8.05 versus the current $11.59 share price and is estimated to have a 76% chance to expire worthless, implying a 26.82% return (39.96% annualized) on cash at risk. On the call side, a $12.00 call bid of $4.10 sold as a covered call against $11.59 stock would yield 38.91% if called at the September 18 expiration, with a 25% chance to expire worthless and a 35.38% (52.71% annualized) YieldBoost; implied volatilities are very elevated (put 159%, call 173%) versus trailing 12‑month realized volatility of 66%.

Analysis

Market structure: Elevated implied vols (put 159%, call 173% vs realized 66%) make OCUL a clear winner for short-vol sellers and income strategies; buyers of upside are the losers paying rich premiums. The $11 put (76% chance to expire worthless per the analytics) and $12 covered-call (25% chance to expire worthless) show asymmetric demand for downside protection and yield — supply of willing premium sellers is limited, keeping IV high into the Sep 18 expiration window. Cross-asset: a binary biotech move would likely re-price small-cap risk premia, pressuring high-yield credit and increasing demand for equity hedges, while FX/commodities unaffected materially.

Risk assessment: Tail risks are classic biotech binaries — negative readouts, FDA adverse actions, or a dilutive secondary can erase 40–80% of market value within days; positive readouts can gap higher similarly. Immediate (days) risk: IV crush or spike around announced catalysts; short term (weeks to Sep 18) risk: assignment or being called away; long term (quarters) risk: cash runway and need to raise capital. Hidden dependencies: option liquidity, borrow costs for hedges, and counterparty concentration in OTC hedges; catalyst calendar (trial filings, investor days) within 30–90 days is the critical monitor.

Trade implications: Direct plays — sell cash‑secured OCUL Sep18 $11 put (collect $2.95 = $295, cash at risk $1,100, target cost basis $8.05) sized to 0.5–2% portfolio as an income/entry tactic; if assigned, hold or hedge. If already long, sell Sep18 $12 covered call for $4.10 to lock a 38.9% gross return to $12; size to limit upside forgone. Add protection: buy a cheap Sep18 $6–$7 put (if available) or tranche short premium to avoid being fully exposed into known catalysts.

Contrarian angles: The consensus income trade (sell premium) underestimates the asymmetric downside from a negative clinical event — IV is likely overstated relative to realized only absent a binary; therefore staggered short‑premium harvesting is superior to a single large sale. Historical parallels: mid‑cap biotechs often see >50% moves on readouts, so premium sellers should cap position size and maintain cash to buy dips rather than rely on assignment. Unintended consequence: being assigned ahead of a capital raise forces liquidity needs; avoid full assignment within 30–90 days if company cash runway is uncertain.

Key Decisions for Investors

• Sell-to-open 1 cash-secured OCUL Sep18 $11 put (collect $295, $1,100 cash at risk) per 100-share lot as a tactical 0.5–2% portfolio position to target $8.05 basis; scale into 2–3 tranches and stop adding if OCUL < $7.50.
• If already long OCUL shares, sell-to-open Sep18 $12 covered calls at $4.10 to harvest ~38.9% gross to $12; limit covered-call exposure to no more than 2–3% of equity allocation to preserve upside for positive binary outcomes.
• Buy protective downside on material positions: purchase one Sep18 OCUL $6–$7 put (or nearest available) per 100 shares owned as a hedge if you expect a readout within 30–60 days, or fund hedges by selling staggered short puts across expirations.
• Avoid concentrated long exposure >2% of portfolio into a single biotech binary; monitor for signs of imminent secondary (unusual option/stock volume, Form S‑3 or financing rumors) and reduce exposure if cash runway implied <6–9 months.